Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus.

Lo MK, Amblard F, Flint M, Chatterjee P, Kasthuri M, Li C, Russell O, Verma K, Bassit L, Schinazi RF, Nichol ST, Spiropoulou CF.

Antiviral Res. 2020 Mar;175:104712. doi: 10.1016/j.antiviral.2020.104712. Epub 2020 Jan 11.

PMID:
31935422
2.

Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.

Abreu RM, Bassit LC, Tao S, Jiang Y, Ferreira AS, Hori PC, Ganova-Raeva LM, Khudyakov Y, Schinazi RF, Carrilho FJ, Ono SK.

Antivir Ther. 2019 Dec 4. doi: 10.3851/IMP3338. [Epub ahead of print]

PMID:
31799942
3.

Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus.

Liu D, Tedbury PR, Lan S, Huber AD, Puray-Chavez MN, Ji J, Michailidis E, Saeed M, Ndongwe TP, Bassit LC, Schinazi RF, Ralston R, Rice CM, Sarafianos SG.

Viruses. 2019 Nov 8;11(11). pii: E1039. doi: 10.3390/v11111039.

4.

Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice.

Amblard F, Boucle S, Bassit L, Cox B, Sari O, Tao S, Chen Z, Ozturk T, Verma K, Russell O, Rat V, de Rocquigny H, Fiquet O, Boussand M, Di Santo J, Strick-Marchand H, Schinazi RF.

Antimicrob Agents Chemother. 2020 Jan 27;64(2). pii: e01701-19. doi: 10.1128/AAC.01701-19. Print 2020 Jan 27.

PMID:
31712213
5.

Synthesis of 7-trifluoromethyl-7-deazapurine ribonucleoside analogs and their monophosphate prodrugs.

Cho JH, Bassit LC, Amblard F, Schinazi RF.

Nucleosides Nucleotides Nucleic Acids. 2019 Oct 7:1-17. doi: 10.1080/15257770.2019.1674333. [Epub ahead of print]

PMID:
31588837
6.

Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus.

Zandi K, Amblard F, Amichai S, Bassit L, Tao S, Jiang Y, Zhou L, Ollinger Russell O, Mengshetti S, Schinazi RF.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00889-19. doi: 10.1128/AAC.00889-19. Print 2019 Sep.

7.

Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses.

Zandi K, Bassit L, Amblard F, Cox BD, Hassandarvish P, Moghaddam E, Yueh A, Libanio Rodrigues GO, Passos I, Costa VV, AbuBakar S, Zhou L, Kohler J, Teixeira MM, Schinazi RF.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00397-19. doi: 10.1128/AAC.00397-19. Print 2019 Jul.

8.

Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs.

Ovadia R, Khalil A, Li H, De Schutter C, Mengshetti S, Zhou S, Bassit L, Coats SJ, Amblard F, Schinazi RF.

Bioorg Med Chem. 2019 Feb 15;27(4):664-676. doi: 10.1016/j.bmc.2019.01.005. Epub 2019 Jan 9.

9.

Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.

Mengshetti S, Zhou L, Sari O, De Schutter C, Zhang H, Cho JH, Tao S, Bassit LC, Verma K, Domaoal RA, Ehteshami M, Jiang Y, Ovadia R, Kasthuri M, Ollinger Russell O, McBrayer T, Whitaker T, Pattassery J, Pascual ML, Uher L, Lin BY, Lee S, Amblard F, Coats SJ, Schinazi RF.

J Med Chem. 2019 Feb 28;62(4):1859-1874. doi: 10.1021/acs.jmedchem.8b01300. Epub 2019 Feb 7.

PMID:
30653317
10.

Towards HBV curative therapies.

Schinazi RF, Ehteshami M, Bassit L, Asselah T.

Liver Int. 2018 Feb;38 Suppl 1:102-114. doi: 10.1111/liv.13656. Review.

11.

Acute acalculous cholecystitis during zika virus infection in an immunocompromised patient.

Ono SK, Bassit L, Van Vaisberg V, Avancini Ferreira Alves V, Caldini EG, Herman BD, Shabman R, Fedorova NB, Paranaguá-Vezozzo D, Sampaio CT, Lages RB, Terrabuio D, Andraus W, Schinazi RF, Carrilho FJ.

Hepatology. 2018 May;67(5):2051-2054. doi: 10.1002/hep.29682. Epub 2018 Feb 27. No abstract available.

12.

Jak Inhibitors Modulate Production of Replication-Competent Zika Virus in Human Hofbauer, Trophoblasts, and Neuroblastoma cells.

Gavegnano C, Bassit LC, Cox BD, Hsiao HM, Johnson EL, Suthar M, Chakraborty R, Schinazi RF.

Pathog Immun. 2017;2(2):199-218. doi: 10.20411/pai.v2i2.190. Epub 2017 May 24.

13.

Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.

Sari O, Boucle S, Cox BD, Ozturk T, Russell OO, Bassit L, Amblard F, Schinazi RF.

Eur J Med Chem. 2017 Sep 29;138:407-421. doi: 10.1016/j.ejmech.2017.06.062. Epub 2017 Jun 29.

14.

Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network.

Aliota MT, Bassit L, Bradrick SS, Cox B, Garcia-Blanco MA, Gavegnano C, Friedrich TC, Golos TG, Griffin DE, Haddow AD, Kallas EG, Kitron U, Lecuit M, Magnani DM, Marrs C, Mercer N, McSweegan E, Ng LFP, O'Connor DH, Osorio JE, Ribeiro GS, Ricciardi M, Rossi SL, Saade G, Schinazi RF, Schott-Lerner GO, Shan C, Shi PY, Watkins DI, Vasilakis N, Weaver SC.

Antiviral Res. 2017 Aug;144:223-246. doi: 10.1016/j.antiviral.2017.06.001. Epub 2017 Jun 6. Review.

15.

2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.

Zhou S, Mahmoud S, Liu P, Zhou L, Ehteshami M, Bassit L, Tao S, Domaoal RA, Sari O, Schutter C, Amiralaei S, Khalil A, Ollinger Russell O, McBrayer T, Whitaker T, Abou-Taleb N, Amblard F, Coats SJ, Schinazi RF.

J Med Chem. 2017 Jul 13;60(13):5424-5437. doi: 10.1021/acs.jmedchem.7b00067. Epub 2017 Jun 26.

PMID:
28595015
16.

Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs.

Sari O, Bassit L, Gavegnano C, McBrayer TR, McCormick L, Cox B, Coats SJ, Amblard F, Schinazi RF.

Tetrahedron Lett. 2017 Feb 15;58(7):642-644. doi: 10.1016/j.tetlet.2017.01.006. Epub 2017 Jan 4.

17.

Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.

Boucle S, Lu X, Bassit L, Ozturk T, Russell OO, Amblard F, Coats SJ, Schinazi RF.

Bioorg Med Chem Lett. 2017 Feb 15;27(4):904-910. doi: 10.1016/j.bmcl.2017.01.010. Epub 2017 Jan 6.

18.

Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.

Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, Li F, Li B, Liu J, Hou J, Sun J, Wang C, Chen J, Wu V, Wong A, Wong CL, Tsang ST, Wang Y, Bassit L, Tao S, Jiang Y, Hsiao HM, Ke R, Perelson AS, Schinazi RF.

Lancet Gastroenterol Hepatol. 2016 Oct;1(2):97-104. Epub 2016 Jul 25.

19.

Synthesis and antiviral evaluation of fluorinated acyclo-nucleosides and their phosphoramidates.

Mahmoud S, Li H, McBrayer TR, Bassit L, Hammad SF, Coats SJ, Amblard F, Schinazi RF.

Nucleosides Nucleotides Nucleic Acids. 2017 Jan 2;36(1):66-82. doi: 10.1080/15257770.2016.1218023. Epub 2016 Oct 19.

PMID:
27759481
20.

Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.

Boucle S, Bassit L, Ehteshami M, Schinazi RF.

Clin Liver Dis. 2016 Nov;20(4):737-749. doi: 10.1016/j.cld.2016.07.001. Epub 2016 Aug 30. Review.

21.

Characterization of dengue virus 2 growth in megakaryocyte-erythrocyte progenitor cells.

Clark KB, Hsiao HM, Bassit L, Crowe JE Jr, Schinazi RF, Perng GC, Villinger F.

Virology. 2016 Jun;493:162-72. doi: 10.1016/j.virol.2016.03.024. Epub 2016 Apr 6.

22.

β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.

Zhou L, Zhang HW, Tao S, Bassit L, Whitaker T, McBrayer TR, Ehteshami M, Amiralaei S, Pradere U, Cho JH, Amblard F, Bobeck D, Detorio M, Coats SJ, Schinazi RF.

J Med Chem. 2015 Apr 23;58(8):3445-58. doi: 10.1021/jm501874e. Epub 2015 Apr 7.

PMID:
25849312
23.

Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.

Vanpouille C, Lisco A, Grivel JC, Bassit LC, Kauffman RC, Sanchez J, Schinazi RF, Lederman MM, Rodriguez B, Margolis L.

Clin Infect Dis. 2015 Jun 1;60(11):1708-14. doi: 10.1093/cid/civ172. Epub 2015 Mar 3.

24.

Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.

Kennedy EM, Bassit LC, Mueller H, Kornepati AVR, Bogerd HP, Nie T, Chatterjee P, Javanbakht H, Schinazi RF, Cullen BR.

Virology. 2015 Feb;476:196-205. doi: 10.1016/j.virol.2014.12.001. Epub 2014 Dec 29.

25.

Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.

Cho JH, Bondana L, Detorio MA, Montero C, Bassit LC, Amblard F, Coats SJ, Schinazi RF.

Bioorg Med Chem. 2014 Dec 1;22(23):6665-6671. doi: 10.1016/j.bmc.2014.10.003. Epub 2014 Oct 13.

26.

Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Kohler JJ, Nettles JH, Amblard F, Hurwitz SJ, Bassit L, Stanton RA, Ehteshami M, Schinazi RF.

Infect Drug Resist. 2014 Mar 5;7:41-56. doi: 10.2147/IDR.S36247. eCollection 2014. Review.

27.

Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses.

Bondada L, Detorio M, Bassit L, Tao S, Montero CM, Singletary TM, Zhang H, Zhou L, Cho JH, Coats SJ, Schinazi RF.

ACS Med Chem Lett. 2013 Aug 8;4(8):747-751.

28.

Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.

Gavegnano C, Detorio MA, Bassit L, Hurwitz SJ, North TW, Schinazi RF.

Antimicrob Agents Chemother. 2013 Mar;57(3):1262-9. doi: 10.1128/AAC.02012-12. Epub 2012 Dec 21.

29.

Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.

Schinazi RF, Bassit L, Clayton MM, Sun B, Kohler JJ, Obikhod A, Arzumanyan A, Feitelson MA.

Antimicrob Agents Chemother. 2012 Dec;56(12):6186-91. doi: 10.1128/AAC.01483-12. Epub 2012 Sep 17.

30.

Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5'-triphosphates.

Shi J, Zhou L, Zhang H, McBrayer TR, Detorio MA, Johns M, Bassit L, Powdrill MH, Whitaker T, Coats SJ, Götte M, Schinazi RF.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7094-8. doi: 10.1016/j.bmcl.2011.09.089. Epub 2011 Sep 29.

31.

Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.

Zhang HW, Detorio M, Herman BD, Solomon S, Bassit L, Nettles JH, Obikhod A, Tao SJ, Mellors JW, Sluis-Cremer N, Coats SJ, Schinazi RF.

Eur J Med Chem. 2011 Sep;46(9):3832-44. doi: 10.1016/j.ejmech.2011.05.051. Epub 2011 May 30.

32.

Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

Singh IR, Gorzynski JE, Drobysheva D, Bassit L, Schinazi RF.

PLoS One. 2010 Apr 1;5(4):e9948. doi: 10.1371/journal.pone.0009948.

33.

HCV drug discovery aimed at viral eradication.

Schinazi RF, Bassit L, Gavegnano C.

J Viral Hepat. 2010 Feb 1;17(2):77-90. doi: 10.1111/j.1365-2893.2009.01246.x. Epub 2009 Dec 18. Review.

34.

Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.

Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.

Antimicrob Agents Chemother. 2009 Sep;53(9):3715-9. doi: 10.1128/AAC.00392-09. Epub 2009 Jul 13.

35.

Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.

Kim HJ, Sharon A, Bal C, Wang J, Allu M, Huang Z, Murray MG, Bassit L, Schinazi RF, Korba B, Chu CK.

J Med Chem. 2009 Jan 8;52(1):206-13. doi: 10.1021/jm801418v.

36.

Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction.

Kline ER, Bassit L, Hernandez-Santiago BI, Detorio MA, Liang B, Kleinhenz DJ, Walp ER, Dikalov S, Jones DP, Schinazi RF, Sutliff RL.

Cardiovasc Toxicol. 2009 Mar;9(1):1-12. doi: 10.1007/s12012-008-9029-8. Epub 2008 Dec 9.

37.

Approaches for the development of antiviral compounds: the case of hepatitis C virus.

Schinazi RF, Coats SJ, Bassit LC, Lennerstrand J, Nettles JH, Hurwitz SJ.

Handb Exp Pharmacol. 2009;(189):25-51. doi: 10.1007/978-3-540-79086-0_2. Review.

PMID:
19048196
38.
39.

Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1.

Moser MJ, Ruckstuhl M, Larsen CA, Swearingen AJ, Kozlowski M, Bassit L, Sharma PL, Schinazi RF, Prudent JR.

Antimicrob Agents Chemother. 2005 Aug;49(8):3334-40.

40.

A tele-operated mobile ultrasound scanner using a light-weight robot.

Delgorge C, Courrèges F, Al Bassit L, Novales C, Rosenberger C, Smith-Guerin N, Brù C, Gilabert R, Vannoni M, Poisson G, Vieyres P.

IEEE Trans Inf Technol Biomed. 2005 Mar;9(1):50-8.

PMID:
15787007
41.

Hepatitis B virus infection in Haemodialysis Centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology.

Carrilho FJ, Moraes CR, Pinho JR, Mello IM, Bertolini DA, Lemos MF, Moreira RC, Bassit LC, Cardoso RA, Ribeiro-dos-Santos G, Da Silva LC.

BMC Public Health. 2004 Apr 27;4:13.

42.

A prospective study of the prevalence of hepatitis B and C virus co-infection among patients with chronic renal disease under hemodialysis.

Ono-Nita SK, de Moraes CR, Carrilho FJ, Pinho JR, Bassit L, da Silva LC.

J Hepatol. 2004 Apr;40(4):715-6. No abstract available.

PMID:
15030993
43.

Genotype distribution of the GB virus C in citizens of São Paulo City, Brazil.

Nishiya AS, Ribeiro-dos-Santos G, Bassit L, Focaccia R, Chamone DF, Sabino EC.

Rev Inst Med Trop Sao Paulo. 2003 Jul-Aug;45(4):213-6. Epub 2003 Sep 17.

44.

High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.

da Silva LC, Bassit L, Ono-Nita SK, Pinho JR, Nishiya A, Madruga CL, Carrilho FJ.

J Gastroenterol. 2002;37(9):732-6.

PMID:
12375147
45.

New prevalence estimate of TT virus (TTV) infection in low- and high-risk population from São Paulo, Brazil.

Bassit L, Takei K, Hoshino-Shimizu S, Nishiya AS, Sabino EC, Bassitt RP, Focaccia R, D'Amico E, Chamone DF, Ribeiro-Dos-Santos G.

Rev Inst Med Trop Sao Paulo. 2002 Jul-Aug;44(4):233-4.

46.

Prevalence of GB virus C (hepatitis G virus) and risk factors for infection in São Paulo, Brazil.

Ribeiro-dos-Santos G, Nishiya AS, Nascimento CM, Bassit L, Chamone DF, Focaccia R, Eluf-Neto J, Sabino EC.

Eur J Clin Microbiol Infect Dis. 2002 Jun;21(6):438-43. Epub 2002 Jun 18.

PMID:
12111599
47.

Comparative study of two anti-HCV screening tests in a large genotyped population of Brazilian dialysis patients.

Bassit L, Van Heuverswyn H, De Bosschere K, Nishiya AS, Carrilho FJ, Moraes CR, Sablon E.

Eur J Clin Microbiol Infect Dis. 2002 May;21(5):404-6. Epub 2002 May 7. No abstract available.

PMID:
12072929
48.

Phylogenetic classification of TT virus groups based on the N22 region is unreliable.

Lemey P, Salemi M, Bassit L, Vandamme AM.

Virus Res. 2002 Apr 23;85(1):47-59.

PMID:
11955638
49.

Estimated Prevalence of Viral Hepatitis in the General Population of the Municipality of São Paulo, Measured by a Serologic Survey of a Stratified, Randomized and Residence-Based Population.

Focaccia R, da Conceição OJ, Sette H Jr, Sabino E, Bassit L, Nitrini DR, Lomar AV, Lorenço R, Vieira De Souza F, Kiffer CR, Santos EB, Gonzales MP, Sáez-Alquézar A, Riscal JR, Fischer D.

Braz J Infect Dis. 1998 Dec;2(6):269-284.

PMID:
11103019
50.

Chronic hepatitis C virus infections in brazilian patients: association with genotypes, clinical parameters and response to long term alpha interferon therapy

Bassit L, Da Silva LC, Ribeiro-Dos-Santos G, Maertens G, Carrilho FJ, Fonseca LE, Alves VA, Gayotto LC, Pereira AN, Takei K, Chamone D, Saez-Alquezar A.

Rev Inst Med Trop Sao Paulo. 1999 May;41(3):183-9.

Supplemental Content

Loading ...
Support Center